To determine whether there was a correlation between the kinetics or frequency of antibody to mammalian-derived hepatitis C virus (HCV) second envelope protein (E2) and development of chronicity or self-limitation of HCV infections, serial sera were examined for anti-E2, anti-HCV with confirmation with Matrix 2.0 (Abbott Laboratories, Abbott Park, IL), and reverse transcriptase-polymerase chain reaction (RT-PCR) from 6 cases of self-limited infection and 6 cases of chronic infection in chimpanzees, and from 5 cases of self-limited infection and 3 cases of chronic infection in patients. Anti-E2 developed earlier, more frequently, and to higher titer in chimpanzees and patients who were developing chronic infection than in those with self-limited infections. Thus anti-E2 is unlikely to play a role in self-limitation of the infection. However, long-term persistence of anti-E2 correlates with chronic infection. There was little or no correlation between the timing of development of anti-E2 and anti-HCV.
Hepatitis C virus (HCV) is a major cause of human morbidity and mortality. Between 20% and 50% of infections by this virus are self-limited; however, the remainder progress to chronic infections with a high risk of development of cirrhosis and hepatocellular carcinoma. There are an estimated 500 million chronic carriers in the world today. It is important to be able to diagnose self-limitation, which requires no further treatment, and to distinguish it from the onset of chronic infection, which may require treatment.
HCV has a single-stranded genome that codes for a polyprotein of ∼3000 amino acids, composed of, successively, capsid, the first and second envelope proteins (E1 and E2, respectively) and the nonstructural proteins NS2, NS3, NS4 a and b, and NS5 a and b. E2 has been of particular interest because its hypervariable region (HVR) appears to vary under immune selection and may therefore be the site of epitopes that react with neutralizing antibodies [1] [2] [3] . The E2 antigen has been expressed in baculovirus expression systems and in mammalian Received 6 October 1998 cells [4] [5] [6] [7] . However, the latter appears to give the highest reactivity with patient sera.
In the first report that used mammalian-derived E2 for analysis of patient sera, Zaaijer et al. found that this assay was useful in resolving cases with indeterminate Riba-2 results [8] . Twenty-nine of 33 Riba indeterminate positive polymerase chain reaction (PCR) sera had anti-E2 detectable by ELISA, as compared with only 2 of 39 PCR-negative sera. Leon et al. confirmed these results and suggested that E2 should be added to the antigens used in polyvalent screening assays [9] . Yuki et al. found that the prevalence of anti-E2 was related to levels of viremia, being higher in those patients with high levels of circulating HCV PCR reactivity [10] . These authors suggested that their results did not support effective neutralization by anti-E2.
By contrast, Tacke et al. recently reported that sera positive for anti-E2 of hepatitis G virus (HGV) were almost all negative for HGV PCR reactivity, and vice versa, suggesting a role for HGV anti-E2 in controlling the infection [11] . Fournillier-Jacob et al., using an indirect immunofluorescence assay for detection of anti-E2, suggested that the prevalence of anti-E2 increased in patients destined for chronicity [12] . Lee et al. found that anti-E2 was frequently positive in otherwise seronegative chronically HCV-infected immunocompromised hemodialysis patients [13] .
In the present study we report serial determinations of HCV anti-E2, PCR, and anti-HCV from patients and chimpanzees recovering from infection, and from those who became chronically infected. The hypothesis that anti-E2 can control HCV infection is not supported by our results. In contrast, absence of a persisting anti-E2 response correlates with termination of the infection. 
Materials and Methods
Patients. The patients studied were enrolled in a prospective posttransfusion follow-up study done in 1969-1973 [14] . Twelve follow-up sera were obtained over a 9-month period. The sera have been stored at Ϫ70ЊC since that time.
Chimpanzees. The chimpanzees studied were housed at Vilab II, the New York Blood Center's chimpanzee research facility in Robertsfield, Liberia. Animals were housed in groups of at least 2 animals and resocialized into larger groups at the completion of protocols. The animals presently studied had been enrolled in various experiments, mostly using HCV genotype 1b, and were mostly followed after the acute infection for 5-10 years. All sera were stored at Ϫ70ЊC.
Serological assays. Mammalian cell-derived E2 protein was prepared and purified as described elsewhere [7] . Purified E2 protein was coated onto polystyrene beads at 1.5 g/mL. A semiquantitative EIA was developed for measurement of anti-E2 in test human or chimpanzee samples. An anti-E2 unit value was assigned to each test sample by reference to a standard calibration curve generated with a pool of 3 known anti-E2 positive plasmas. All chimpanzee samples were tested undiluted; human samples were tested undiluted or retested at a 1 : 20 dilution if they were initially above the reference curve limits in the undiluted assay. The cut-off for the assay was 15 units. This corresponds to the mean of negative controls plus 6 standard deviations. Testing for anti-HCV antibody was done by using a commercially available HCV antibody assay (HCV 3.0 EIA; Abbott Laboratories, Abbott Park, IL). S/CO 1 (the ratio of OD of the sample to the negative cutoff OD) is 1 positive in this assay. Matrix HCV 2.0 (Abbott Laboratories) was also used to assist in determining when seroconversion to active HCV antibody positive status occurred (data not shown).
PCR assays. Quantitative HCV DNA assays were done by using the AmpliSensor system (Biotronics, Lowell, MA). The AmpliSensor assay system monitors the amplification efficiency of the PCR reaction via a fluorescence resonance energy transfer (FRET)-based detection scheme [15] . HCV RNA was reverse-transcribed within the 5 untranslated region (5 UTR). The cDNA was amplified in an asymmetric manner to generate a 211 nucleotidelong single-strand target DNA. The single-strand products were reamplified in a seminested manner with the fluorescent primer duplex, yielding a 66-bp amplicon. The in vitro transcript of pHCV 324 (Biotronics) was used as a standard for quantitation. Serial dilutions of this transcript were run as a standard in duplicate in every run. The Acugene system is based on serial fluorescence measurements done between the 26th and 41st PCR cycle. Thus microplates are sealed throughout the cycling procedure, and are never opened after the 25th cycle when fluorescent primers are added. This contributes greatly to the control of contamination. This assay detects 50-100 RNA molecules per reaction. PCR set up is done in a laminar flow hood in a dedicated room from which plasmids and amplicons are excluded. Statistical analysis. The estimate of the probability that a subject remains anti-E2 negative at any time was calculated by the Kaplan-Meier method [16] . The log-rank test was used for the comparison of time to conversion in self-limited and chronic human and chimpanzee subjects. Figure 1 summarizes the 6 cases of HCV infection from chimpanzees that developed chronic infection as assessed by PCR. A rapid and strong anti-HCV response was seen in all animals. Anti-HCV E2 responses occurred in all animals, although in 2 cases this occurred late in follow-up. Times of seroconversion in these and the other cases studied are summarized in table 1.
Results
Data from the chimpanzees that developed self-limited infection are summarized in figure 2 . Four of these animals did not develop anti-E2 despite many years of follow-up. The remaining 2 animals in this group had only early transitory anti-E2 responses. Anti-HCV responses were rapid and strong and did not differ from the animals that developed chronic infection.
A Kaplan-Meier plot of these data is shown in figure 3 . The difference in time to seroconversion between chronic and selflimited infection is statistically significant ( ). P ! .05 Figures 4 and 5 summarize the human cases. These differ from the chimpanzee cases in that many (case nos. 35, 4, 67, 201, and 155) show passive antibody resulting from the large number of transfusions received (mean, 18), poor donor selection, and the absence of anti-HCV screening at the time that the study was done. The cases developing chronic infection (figure 3) all developed strong anti-E2 responses. In 2 cases these responses were rapid. Two of the cases developing selflimited infections (figure 4) developed anti-E2, though more slowly than cases developing chronicity ( ) and to lower P ! .05 peak titers ( ). Two of these patients developed no de-P ! .05 tectable anti-E2.
A Kaplan-Meier plot of the human data is shown in figure  6 . The difference in time to anti-E2 seroconversion between chronic and self-limited infections is significant ( ). P ! .05
Discussion
The present study, which used mammalian recombinantderived E2 as a reagent, showed that chimpanzees developing chronic infection showed a higher frequency of development of anti-E2, and higher anti-E2 titers, than chimpanzees developing self-limited infections. Humans developing chronic infection showed a more rapid and higher titer anti-E2 response than those developing self-limited infection. These studies indicate that anti-E2 does not play a role in the mechanism of selflimitation of HCV infections, as might be thought. The higher titer of anti-E2 in chronic infections undoubtedly reflects stronger and long-lasting E2 antigen production in this type of infection.
Our findings are compatible with those of Yuki et al., who found anti-E2 to correlate with high PCR levels [10] , and with the findings of Fournillier-Jacob et al. and Grellier et al., who found that anti-E2 was more prevalent in patients developing chronic infections [12, 17] . It is surprising that opposite results have been obtained in hepatis G virus infection, where Tacke et al. have reported that anti-HGV E2 correlated with selflimitation as assessed by the absence of PCR reactivity [11] .
Allander et al. have reported data suggesting that antibody to an E2 HVR one (HVR1) peptide appears in patients earlier than antibody to recombinant E2 protein, and that early appearance of antibodies to HVR1 may predict clearance of HCV infection [18] . This hypothesis requires further study in larger numbers of patients.
